FORM D

Notice of Exempt Offering of Securities

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	Vone None	Entity Type
0001372514			Corporation
Name of Issuer			C Limited Partnership
EYEGATE PHARMACEUTICALS INC			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organizat	ion		C Other
Over Five Years Ago			
C Within Last Five Years (Specify Year)			

C Yet to Be Formed

## 2. Principal Place of Business and Contact Information

Name of issuer			
EYEGATE PHARMACEUTIC	ALS INC		
Street Address 1	Sti	reet Address 2	
100 BEAVER STREET			
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
WALTHAM	МА	02453	781-788-9043

## 3. Related Persons

Last Name		First Name			Middle	Name
From		Stephen	Stephen		]	
Street Address 1			;	Street Address 2	1	
c/o Eyegate Pharmaceuticals, Inc.				100 Beaver Stre	et	
City		State/Province/	Coun	try	ZIP/Pos	stal Code
Waltham		MA			02453	
Relationship:	Execut	ive Officer	~	Director		Promoter
Last Name		First Name			Middle	Name
Cleftie		J.			Sebast	tien
Street Address 1			;	Street Address 2		
c/o Innoven Partnena	ires		[	10, rue de la Pai	x	
City		State/Province/	Coun	try	ZIP/Pos	stal Code
Paris		10			75002	
Relationship:	Execut	ive Officer	2	Director		Promoter

Goldberg

Street Address 1

Morton

Street Address 2

Last Name	First Name		Middle Name	
Maiore	Alain			
Street Address 1		Street Address 2	 2	
c/o Ventech	]	5-7 rue de Mor	nttessuy	_
City	State/Province/	Country	ZIP/Postal Code	
Paris	10		75340	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Resp	onse (if Necessary)		1	
Last Name	First Name		Middle Name	
Mullen	Michael			
Street Address 1		Street Address 2	2	
97 Wolf Pond Rd				
City	State/Province/	Country	ZIP/Postal Code	
Kingston	МА		02364	
Relationship:	Executive Officer	Director	Promoter	
Hancock	Thomas		<b>E.</b>	
Street Address 1		Street Address 2		
c/o New England	Partners Capital, L.P.	400 Crown Co	lony Drive, Suite 104	
City	State/Province/	Country	ZIP/Postal Code	
Quincy	МА		02169	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Resp	opso (if Nooossary)	Perend)	P	
Clarincation of Kesp	blise (li ivecessai y)			
Last Name	First Name		Middle Name	
Chaney	Paul			
Street Address 1	ij [Ľ	Street Address 2	<u>-</u> 1 2	
c/o OSI Pharmace	euticals, Inc.	41 Pinelawn R		
City	State/Province/		ZIP/Postal Code	
Melville	NY	e/	11747	
Relationship:	Executive Officer	Director	Promoter	
<b>r</b> .		and an obtain		
Clarification of Resp	onse (if Necessary)			
N				

c/o Eyegate Pharmaceuticals, Ind	2.	100 Beaver Stree	et
City	State/Province/	Country	ZIP/Postal Code
Waltham	MA		02453
Relationship: 🔲 Execu	tive Officer	Director	Promoter
Clarification of Response (if Necessar Last Name	y) First Name		Middle Name
Tyle	Praveen		]
Street Address 1		Street Address 2	1
c/o Eyegate Pharmaceuticals, Inc		100 Beaver Stree	et
City	State/Province/	Country	ZIP/Postal Code
Waltham	MA		02453
Relationship: Execu	tive Officer	Director	Promoter
Clarification of Response (if Necessar	v)		

### 4. Industry Group

## C Agriculture

#### **Banking & Financial Services**

- C Commercial Banking
- C Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund
- Other Banking & Financial

### C Business Services

#### Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

- Health Care
- BiotechnologyHealth Insurance
- C Hospitals & Physicians
- C Pharmaceuticals
- C Other Health Care

C Manufacturing

Real Estate

C

C Commercial

C Construction

C Residential

**REITS & Finance** 

O Other Real Estate

- Other Health Care
- C Other Technology

C Retailing

C Restaurants

Technology

C Computers

#### Travel

C Airlines & Airports

**C** Telecommunications

- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel
- O Other

### 5. Issuer Size

#### **Revenue Range**

- C No Revenues
- C \$1 \$1,000,000
- C \$1,000,001 \$5,000,000
- \$5,000,001 \$25,000,000
- \$25,000,001 \$100,000,000
- Over \$100,000,000
- O Decline to Disclose
- C Not Applicable

### Aggregate Net Asset Value Range

- C No Aggregate Net Asset Value
- S1 \$5,000,000
- C \$5,000,001 \$25,000,000
- C \$25,000,001 \$50,000,000
- C \$50,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
- C Not Applicable

	<ol><li>Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)</li></ol>							
	Rule 504(b)(1) (not (i), (ii) or (iii))		Rule 505					
	Rule 504 (b)(1)(i)		Rule 506(b)					
Π	Rule 504 (b)(1)(ii)		□ Rule 506(c)					
	Rule 504 (b)(1)(iii)		Securities Act Section 4(a)(5)					
	Investment Company Act Section 3(c)							

7.	Type of Fil	ing		
•	New Notice	Date of First Sale	2009-12-08	First Sale Yet to Occur

☐ Amendment

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

C Yes C No

## 9. Type(s) of Securities Offered (select all that apply)

Γ	Pooled Investment Fund Interests	$\mathbf{V}$	Equity
Г	Tenant-in-Common Securities	$\Box$	Debt
Π	Mineral Property Securities		Option, Warrant or Other Right to Acquire Another Security
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Π	Other (describe)

### 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? O Yes ightarrow No

Clarification of Response (if Necessary)

11. Minimum Investment	
Minimum investment accepted from any outside \$	USD
12. Sales Compensation	
Recipient   (Associated) Broker or Dealer None	Recipient CRD Number None   (Associated) Broker or Dealer CRD None   Number None
	Street Address 2

# 13. Offering and Sales Amounts

TS. Oliening and Sales Amounts
Total Offering Amount 💲 22641695 USD 🗖 Indefinite
Total Amount Sold \$ 11081232 USD
Total Remaining to be \$ 11560463 USD Indefinite
Clarification of Response (if Necessary)
Amount includes investments made by foreign entities.
rinount includes investments inder by toreign entities.
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$ 0 USD Estimate
Finders' Fees \$ 0 USD Estimate
Clarification of Response (if Necessary)
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$ USD Estimate
Clarification of Response (if Necessary)
Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
EYEGATE PHARMACEUTIC INC	ALS /s/ Stephen Fro	om Stephen From	President	2009-12-21